The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Peptide-based Drug Market Research Report 2025
Synopsis
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less.
The global Peptide-based Drug market was valued at US$ 35410 million in 2023 and is anticipated to reach US$ 62200 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.
The Peptide Drug market is driven by the increasing recognition of peptides as a versatile and promising class of therapeutics. Peptides offer the potential to target specific biological pathways and cellular functions with high specificity, making them valuable candidates for treating a wide range of diseases, including cancer, metabolic disorders, and cardiovascular conditions. The growing understanding of peptide structure-activity relationships, coupled with advancements in peptide synthesis and modification techniques, contribute to the development of more stable and bioavailable peptide drugs, fostering market growth. Moreover, the rise in personalized medicine approaches and the need for more targeted therapies align with the development of peptide-based treatments that can be tailored to individual patient profiles. However, the market also faces challenges, including optimizing peptide delivery systems, enhancing bioavailability, and addressing potential immunogenicity and stability issues. Additionally, the complexity of peptide synthesis, the need for stringent regulatory approvals, and the competition from other therapeutic modalities pose obstacles for manufacturers and researchers. To succeed, stakeholders must focus on innovative peptide design, efficient synthesis methods, and comprehensive pre-clinical and clinical studies to demonstrate the safety and efficacy of peptide drugs. Addressing challenges while harnessing the therapeutic potential of peptides will be essential for driving the growth and adoption of peptide-based treatments in various medical applications.
This report aims to provide a comprehensive presentation of the global market for Peptide-based Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide-based Drug.
Report Scope
The Peptide-based Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide-based Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide-based Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Segment by Type
Injection
Oral
Other
Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide-based Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less.
The global Peptide-based Drug market was valued at US$ 35410 million in 2023 and is anticipated to reach US$ 62200 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.
The Peptide Drug market is driven by the increasing recognition of peptides as a versatile and promising class of therapeutics. Peptides offer the potential to target specific biological pathways and cellular functions with high specificity, making them valuable candidates for treating a wide range of diseases, including cancer, metabolic disorders, and cardiovascular conditions. The growing understanding of peptide structure-activity relationships, coupled with advancements in peptide synthesis and modification techniques, contribute to the development of more stable and bioavailable peptide drugs, fostering market growth. Moreover, the rise in personalized medicine approaches and the need for more targeted therapies align with the development of peptide-based treatments that can be tailored to individual patient profiles. However, the market also faces challenges, including optimizing peptide delivery systems, enhancing bioavailability, and addressing potential immunogenicity and stability issues. Additionally, the complexity of peptide synthesis, the need for stringent regulatory approvals, and the competition from other therapeutic modalities pose obstacles for manufacturers and researchers. To succeed, stakeholders must focus on innovative peptide design, efficient synthesis methods, and comprehensive pre-clinical and clinical studies to demonstrate the safety and efficacy of peptide drugs. Addressing challenges while harnessing the therapeutic potential of peptides will be essential for driving the growth and adoption of peptide-based treatments in various medical applications.
This report aims to provide a comprehensive presentation of the global market for Peptide-based Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide-based Drug.
Report Scope
The Peptide-based Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide-based Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide-based Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Segment by Type
Injection
Oral
Other
Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide-based Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide-based Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Injection
1.2.3 Oral
1.2.4 Other
1.3 Market by Application
1.3.1 Global Peptide-based Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Central Nervous System
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide-based Drug Market Perspective (2019-2030)
2.2 Peptide-based Drug Growth Trends by Region
2.2.1 Global Peptide-based Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Peptide-based Drug Historic Market Size by Region (2019-2024)
2.2.3 Peptide-based Drug Forecasted Market Size by Region (2025-2030)
2.3 Peptide-based Drug Market Dynamics
2.3.1 Peptide-based Drug Industry Trends
2.3.2 Peptide-based Drug Market Drivers
2.3.3 Peptide-based Drug Market Challenges
2.3.4 Peptide-based Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide-based Drug Players by Revenue
3.1.1 Global Top Peptide-based Drug Players by Revenue (2019-2024)
3.1.2 Global Peptide-based Drug Revenue Market Share by Players (2019-2024)
3.2 Global Peptide-based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide-based Drug Revenue
3.4 Global Peptide-based Drug Market Concentration Ratio
3.4.1 Global Peptide-based Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide-based Drug Revenue in 2023
3.5 Peptide-based Drug Key Players Head office and Area Served
3.6 Key Players Peptide-based Drug Product Solution and Service
3.7 Date of Enter into Peptide-based Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide-based Drug Breakdown Data by Type
4.1 Global Peptide-based Drug Historic Market Size by Type (2019-2024)
4.2 Global Peptide-based Drug Forecasted Market Size by Type (2025-2030)
5 Peptide-based Drug Breakdown Data by Application
5.1 Global Peptide-based Drug Historic Market Size by Application (2019-2024)
5.2 Global Peptide-based Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Peptide-based Drug Market Size (2019-2030)
6.2 North America Peptide-based Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Peptide-based Drug Market Size by Country (2019-2024)
6.4 North America Peptide-based Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide-based Drug Market Size (2019-2030)
7.2 Europe Peptide-based Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Peptide-based Drug Market Size by Country (2019-2024)
7.4 Europe Peptide-based Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide-based Drug Market Size (2019-2030)
8.2 Asia-Pacific Peptide-based Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Peptide-based Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Peptide-based Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide-based Drug Market Size (2019-2030)
9.2 Latin America Peptide-based Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Peptide-based Drug Market Size by Country (2019-2024)
9.4 Latin America Peptide-based Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide-based Drug Market Size (2019-2030)
10.2 Middle East & Africa Peptide-based Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Peptide-based Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Peptide-based Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Peptide-based Drug Introduction
11.1.4 Sanofi Revenue in Peptide-based Drug Business (2019-2024)
11.1.5 Sanofi Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Peptide-based Drug Introduction
11.2.4 Teva Revenue in Peptide-based Drug Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Detail
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Peptide-based Drug Introduction
11.3.4 Novo Nordisk Revenue in Peptide-based Drug Business (2019-2024)
11.3.5 Novo Nordisk Recent Development
11.4 Takeda
11.4.1 Takeda Company Detail
11.4.2 Takeda Business Overview
11.4.3 Takeda Peptide-based Drug Introduction
11.4.4 Takeda Revenue in Peptide-based Drug Business (2019-2024)
11.4.5 Takeda Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Detail
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Peptide-based Drug Introduction
11.5.4 Eli Lilly Revenue in Peptide-based Drug Business (2019-2024)
11.5.5 Eli Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Peptide-based Drug Introduction
11.6.4 AstraZeneca Revenue in Peptide-based Drug Business (2019-2024)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Peptide-based Drug Introduction
11.7.4 Novartis Revenue in Peptide-based Drug Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Detail
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Peptide-based Drug Introduction
11.8.4 AbbVie Revenue in Peptide-based Drug Business (2019-2024)
11.8.5 AbbVie Recent Development
11.9 Ipsen
11.9.1 Ipsen Company Detail
11.9.2 Ipsen Business Overview
11.9.3 Ipsen Peptide-based Drug Introduction
11.9.4 Ipsen Revenue in Peptide-based Drug Business (2019-2024)
11.9.5 Ipsen Recent Development
11.10 Ferring
11.10.1 Ferring Company Detail
11.10.2 Ferring Business Overview
11.10.3 Ferring Peptide-based Drug Introduction
11.10.4 Ferring Revenue in Peptide-based Drug Business (2019-2024)
11.10.5 Ferring Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Peptide-based Drug Introduction
11.11.4 Merck Revenue in Peptide-based Drug Business (2019-2024)
11.11.5 Merck Recent Development
11.12 The Medicines
11.12.1 The Medicines Company Detail
11.12.2 The Medicines Business Overview
11.12.3 The Medicines Peptide-based Drug Introduction
11.12.4 The Medicines Revenue in Peptide-based Drug Business (2019-2024)
11.12.5 The Medicines Recent Development
11.13 J & J
11.13.1 J & J Company Detail
11.13.2 J & J Business Overview
11.13.3 J & J Peptide-based Drug Introduction
11.13.4 J & J Revenue in Peptide-based Drug Business (2019-2024)
11.13.5 J & J Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Peptide-based Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Injection
Table 3. Key Players of Oral
Table 4. Key Players of Other
Table 5. Global Peptide-based Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Peptide-based Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Peptide-based Drug Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Peptide-based Drug Market Share by Region (2019-2024)
Table 9. Global Peptide-based Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Peptide-based Drug Market Share by Region (2025-2030)
Table 11. Peptide-based Drug Market Trends
Table 12. Peptide-based Drug Market Drivers
Table 13. Peptide-based Drug Market Challenges
Table 14. Peptide-based Drug Market Restraints
Table 15. Global Peptide-based Drug Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Peptide-based Drug Market Share by Players (2019-2024)
Table 17. Global Top Peptide-based Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-based Drug as of 2023)
Table 18. Ranking of Global Top Peptide-based Drug Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Peptide-based Drug Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peptide-based Drug Product Solution and Service
Table 22. Date of Enter into Peptide-based Drug Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peptide-based Drug Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Peptide-based Drug Revenue Market Share by Type (2019-2024)
Table 26. Global Peptide-based Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Peptide-based Drug Revenue Market Share by Type (2025-2030)
Table 28. Global Peptide-based Drug Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Peptide-based Drug Revenue Market Share by Application (2019-2024)
Table 30. Global Peptide-based Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Peptide-based Drug Revenue Market Share by Application (2025-2030)
Table 32. North America Peptide-based Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Peptide-based Drug Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Peptide-based Drug Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Peptide-based Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Peptide-based Drug Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Peptide-based Drug Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Peptide-based Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Peptide-based Drug Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Peptide-based Drug Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Peptide-based Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Peptide-based Drug Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Peptide-based Drug Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Peptide-based Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Peptide-based Drug Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Peptide-based Drug Market Size by Country (2025-2030) & (US$ Million)
Table 47. Sanofi Company Detail
Table 48. Sanofi Business Overview
Table 49. Sanofi Peptide-based Drug Product
Table 50. Sanofi Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 51. Sanofi Recent Development
Table 52. Teva Company Detail
Table 53. Teva Business Overview
Table 54. Teva Peptide-based Drug Product
Table 55. Teva Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 56. Teva Recent Development
Table 57. Novo Nordisk Company Detail
Table 58. Novo Nordisk Business Overview
Table 59. Novo Nordisk Peptide-based Drug Product
Table 60. Novo Nordisk Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 61. Novo Nordisk Recent Development
Table 62. Takeda Company Detail
Table 63. Takeda Business Overview
Table 64. Takeda Peptide-based Drug Product
Table 65. Takeda Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 66. Takeda Recent Development
Table 67. Eli Lilly Company Detail
Table 68. Eli Lilly Business Overview
Table 69. Eli Lilly Peptide-based Drug Product
Table 70. Eli Lilly Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 71. Eli Lilly Recent Development
Table 72. AstraZeneca Company Detail
Table 73. AstraZeneca Business Overview
Table 74. AstraZeneca Peptide-based Drug Product
Table 75. AstraZeneca Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 76. AstraZeneca Recent Development
Table 77. Novartis Company Detail
Table 78. Novartis Business Overview
Table 79. Novartis Peptide-based Drug Product
Table 80. Novartis Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. AbbVie Company Detail
Table 83. AbbVie Business Overview
Table 84. AbbVie Peptide-based Drug Product
Table 85. AbbVie Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 86. AbbVie Recent Development
Table 87. Ipsen Company Detail
Table 88. Ipsen Business Overview
Table 89. Ipsen Peptide-based Drug Product
Table 90. Ipsen Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 91. Ipsen Recent Development
Table 92. Ferring Company Detail
Table 93. Ferring Business Overview
Table 94. Ferring Peptide-based Drug Product
Table 95. Ferring Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 96. Ferring Recent Development
Table 97. Merck Company Detail
Table 98. Merck Business Overview
Table 99. Merck Peptide-based Drug Product
Table 100. Merck Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 101. Merck Recent Development
Table 102. The Medicines Company Detail
Table 103. The Medicines Business Overview
Table 104. The Medicines Peptide-based Drug Product
Table 105. The Medicines Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 106. The Medicines Recent Development
Table 107. J & J Company Detail
Table 108. J & J Business Overview
Table 109. J & J Peptide-based Drug Product
Table 110. J & J Revenue in Peptide-based Drug Business (2019-2024) & (US$ Million)
Table 111. J & J Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide-based Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Peptide-based Drug Market Share by Type: 2023 VS 2030
Figure 3. Injection Features
Figure 4. Oral Features
Figure 5. Other Features
Figure 6. Global Peptide-based Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Peptide-based Drug Market Share by Application: 2023 VS 2030
Figure 8. Cancer Case Studies
Figure 9. Metabolic Disorders Case Studies
Figure 10. Central Nervous System Case Studies
Figure 11. Other Case Studies
Figure 12. Peptide-based Drug Report Years Considered
Figure 13. Global Peptide-based Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Peptide-based Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Peptide-based Drug Market Share by Region: 2023 VS 2030
Figure 16. Global Peptide-based Drug Market Share by Players in 2023
Figure 17. Global Top Peptide-based Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-based Drug as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Peptide-based Drug Revenue in 2023
Figure 19. North America Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Peptide-based Drug Market Share by Country (2019-2030)
Figure 21. United States Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Peptide-based Drug Market Share by Country (2019-2030)
Figure 25. Germany Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Peptide-based Drug Market Share by Region (2019-2030)
Figure 33. China Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Peptide-based Drug Market Share by Country (2019-2030)
Figure 41. Mexico Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Peptide-based Drug Market Share by Country (2019-2030)
Figure 45. Turkey Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Peptide-based Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Sanofi Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 48. Teva Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 49. Novo Nordisk Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 50. Takeda Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 51. Eli Lilly Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 52. AstraZeneca Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 53. Novartis Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 54. AbbVie Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 55. Ipsen Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 56. Ferring Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 57. Merck Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 58. The Medicines Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 59. J & J Revenue Growth Rate in Peptide-based Drug Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
